RGB-286638 - 10mM in DMSO, high purity , CAS No.784210-87-3(DMSO)

Item Number

R655074

• Specifications & Purity: 10mM in DMSO
• Storage Temp: Desiccated,Store at -80°C
• Shipped In: Ice chest + Ice pads

Product Description

RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9 , cyclin B1-CDK1 , cyclin E-CDK2 , cyclin D1-CDK4 , cyclin E-CDK3 , and p35-CDK5 with IC 50 s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β , TAK1, Jak2 and MEK1 , with IC 50 s of 3, 5, 50, and 54 nM.

In Vitro

RGB-286638 is an indenopyrazole-derived CDK inhibitor (CDKI) with K i -nanomolar activity against transcriptional CDKs. RGB-286638 inhibits several tyrosine and serine/threonine non-CDK enzymes, i.e. GSK-3β, TAK1, AMPK, Jak2, MEK1. The dose- and time-dependent effect of treatment with RGB-286638 (12.5-100nM) is investigated on the growth of human p53-wt (MM.1S, MM.1R, and H929) and p53-mutant (U266, OPM1, and RPMI) MM cells by MTT assay, assessing viability at 24 and 48 hours. The half-maximally effective concentrations (EC 50 ) range between 20 and 70 nM at 48 hours. Dose-dependent differences in growth among p53-wt and -mutant cells are observed after 50nM treatment, with p53-wt MM.1S, MM.1R and H929 being slightly more sensitive to RGB-286638 treatment at 48h. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Dose-finding studies with RGB-286638 identify 40 mg/kg/day IV treatment as the maximum tolerated dose in SCID mice. Five days IV treatment with RGB-286638 significantly suppresses MM tumor growth, with maximum TGI (%) noted at day 14 following end of treatment at 85.06% and 86.34% in the 30 mg/kg and 40 mg/kg treated cohorts respectively. The log10 cell kill (LCK Td: 4.5 days) is 1.6 for both treated groups. RGB-286638 treatment is also associated with improved survival, evidenced by first death at day 24 in controls versus day 43 in both treated groups. No toxic deaths occurred during this study: maximum percentage of body weight (BW) loss is observed on day 5 (8.4%) at 30 mg/kg dosage schedule, and on day 15 (9.9%) after 40 mg/kg dosing, with weight recovery in the following two weeks . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:T1-CDK9 1 nM (IC 50 ) cyclin B1-CDK1 2 nM (IC 50 ) cyclin E-CDK2 3 nM (IC 50 ) cyclin D1-CDK4 4 nM (IC 50 ) cyclin E-CDK3 5 nM (IC 50 ) p35-CDK5 5 nM (IC 50 ) cyclin H-CDK7 44 nM (IC 50 ) cyclin D3-CDK6 55 nM (IC 50 ) GSK-3β 3 nM (IC 50 ) JAK2 50 nM (IC 50 ) MEK1 54 nM (IC 50 ) Fms 1 nM (IC 50 ) TAK1 5 nM (IC 50 ) JNK1a1 17 nM (IC 50 ) JNK1a2 40 nM (IC 50 ) C-src 25 nM (IC 50 ) AMPK 41 nM (IC 50 )